Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
Open Access
- 11 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-13
- https://doi.org/10.1038/s41467-021-21241-0
Abstract
T cell rejuvenation by PD-1/PD-L1 blockade, despite emerging as a highly promising therapy for advanced cancers, is only beneficial for a minority of treated patients. There is evidence that a lack of efficient T cell activation may be responsible for the failure. Here, we demonstrate that IL-21 can be targeted to tumor-reactive T cells by fusion of IL-21 to anti-PD-1 antibody. To our surprise, the fusion protein PD-1Ab21 promotes the generation of memory stem T cells (TSCM) with enhanced cell proliferation. PD-1Ab21 treatment show potent antitumor effects in established tumor-bearing mice accompanied with an increased frequency of TSCM and robust expansion of tumor-specific CD8+ T cells with a memory phenotype, and is superior to a combination of PD-1 blockade and IL-21 infusion. Therefore, we have developed a potential strategy to improve the therapeutic effects of immune checkpoint blockade by simultaneously targeting cytokines to tumor-reactive T cells.Keywords
This publication has 50 references indexed in Scilit:
- Defining and Understanding Adaptive Resistance in Cancer ImmunotherapyTrends in Immunology, 2018
- Immune Checkpoint Blockade across the Cancer Care ContinuumImmunity, 2018
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination TherapiesCancer Cell, 2018
- Mechanisms of resistance to immune checkpoint inhibitorsBritish Journal of Cancer, 2018
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseNature, 2017
- Regulation of effector and memory CD8+ T cell function by inflammatory cytokinesCytokine, 2016
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapyBlood, 2008
- Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and functionThe Journal of Experimental Medicine, 2005
- IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-21The Journal of Immunology, 2004